Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection.
Journal article
Liu C. et al, (2024), Nature communications, 15
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.
Journal article
Zhou D. et al, (2024), Nature communications, 15
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history
Journal article
Hornsby H. et al, (2023), Nature Communications, 14
Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody.
Journal article
Keelapang P. et al, (2023), Microbiology spectrum
Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
Journal article
Thursz M. et al, (2023), The Journal of general virology, 104
Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
Journal article
Thursz M. et al, (2023), The Journal of general virology, 104
Accelerating drug target inhibitor discovery with a deep generative foundation model.
Journal article
Chenthamarakshan V. et al, (2023), Science advances, 9
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.
Journal article
Ragonnet-Cronin M. et al, (2023), Nature communications, 14
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
Journal article
Wei J. et al, (2023), Nature Communications, 14
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.
Journal article
Buckell J. et al, (2023), Scientific reports, 13
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination
Journal article
Yin Z. et al, (2023), Cell Reports, 42, 112470 - 112470
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Journal article
Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
Journal article
Moore SC. et al, (2023), Med, 4, 191 - 215.e9
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region
Journal article
Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
Journal article
Huo J. et al, (2023), Cell Reports, 42, 111903 - 111903
Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies
Journal article
Davies AJ. et al, (2023), Neurology - Neuroimmunology Neuroinflammation, 10, e200047 - e200047
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.
Journal article
Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8
CryoEM structures of the multimeric secreted NS1, a major factor for dengue hemorrhagic fever.
Journal article
Shu B. et al, (2022), Nature communications, 13